Pharmala Biotech Holdings Inc. MDXXF
OTC PK
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -48.07% | 16.29% | -11.47% | 29.39% | 34.17% |
| Total Depreciation and Amortization | 2.00% | 2.04% | 2.08% | -53.62% | 1.97% |
| Total Amortization of Deferred Charges | 0.00% | 1.74% | -1.71% | -- | -- |
| Total Other Non-Cash Items | 86.39% | -8.52% | 291.40% | -139.80% | -56.15% |
| Change in Net Operating Assets | -14.75% | -167.72% | -0.85% | 184.54% | -41.68% |
| Cash from Operations | -22.79% | -118.87% | 61.30% | -17.61% | -3.45% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -0.83% | 78.22% | -25.78% | 78.24% | 109.97% |
| Cash from Investing | -0.83% | 78.22% | -24.75% | 75.81% | 109.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -- | -- | -- | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -166.20% | -30.32% | 147.40% | 32.16% | -306.42% |